Skip to main contentSkip to main content
You have permission to edit this article.
Edit

Premature Cardiovascular Disease Linked to Lower Cognition

  • Updated
  • 0
Premature Cardiovascular Disease Linked to Lower Cognition

WEDNESDAY, Jan. 25, 2023 (HealthDay News) -- Premature cardiovascular disease (CVD; age 60 years or younger) is associated with lower cognition, according to a study published online Jan. 25 in Neurology.

Xiaqing Jiang, M.D., Ph.D., M.P.H., from the University of California in San Francisco, and colleagues examined the association of premature CVD with midlife cognition and white matter health among 3,146 participants in the Coronary Artery Risk Development in Young Adults study, who were aged 18 to 30 years at baseline in 1985 to 1986 and were followed for up to 30 years. Five cognitive tests measuring different domains were administered at follow-up. In a subset of 656 participants, brain magnetic resonance imaging measures of white matter hyperintensity and white matter integrity were available.

The researchers found that 147 participants (5 percent) had premature CVD. Premature CVD was associated with lower cognition in four of five domains after adjustment for multiple variables: global cognition (−0.22), verbal memory (−0.28), processing speed (−0.46), and executive function (−0.38). After adjustment for covariates, premature CVD was associated with greater white matter hyperintensity (total, temporal, and parietal lobes) and higher white matter mean diffusivity (total and temporal lobes). After adjustment for cardiovascular risk factors and excluding those with stroke/transient ischemic attack, these associations remained significant. There was also an association seen for premature CVD with accelerated cognitive decline over five years (adjusted odds ratio, 3.07).

"Our research suggests that a person's 20s and 30s are a crucial time to begin protecting brain health through cardiovascular disease prevention and intervention," Jiang said in a statement.

Abstract/Full Text (subscription or payment may be required)

0 Comments
0
0
0
0
0

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Scientists say delivering gene therapy directly to the brain holds great promise. The first brain-delivered gene therapy on the market was recently approved in Europe and the U.K. for a rare genetic disorder called AADC deficiency. It causes developmental delays and movement disorders in kids. New Jersey drugmaker PTC Therapeutics plans to seek approval for the treatment in the U.S. this year. Meanwhile, about 30 studies in the U.S. are testing gene therapy directly to the brain for other disorders, including Alzheimer’s and Parkinson’s. Challenges remain, especially with diseases caused by more than a single gene. But scientists say the evidence supporting this approach is mounting.

This year's North Carolina General Assembly session begins in earnest on Wednesday, two weeks after lawmakers met to pick leaders. While the legislature starts from scratch when each odd-numbered year begins, there should be plenty of familiar issues. They include whether to approve Medicaid expansion, medical marijuana and sports gambling. Republicans also are likely to try to enact looser gun laws and tougher immigration directives given they hold a veto-proof majority in the Senate and are just one seat short in the House. Gov. Roy Cooper and fellow Democrats aim to block more restrictive abortion rules in light of the Supreme Court ruling striking down Roe v. Wade.

A phone’s camera lens can measure a heart rate. The microphone, kept by the bedside, can screen for sleep apnea. Even the speaker is being tapped, to monitor breathing. But using smartphones as diagnostic tools is a work in progress, experts say.

President Joe Biden is expected to name the man who ran his administration’s initial response to the COVID-19 pandemic as his next chief of staff. Word of Jeff Zients' hiring comes from two people familiar with the matter who spoke to The Associated Press on condition of anonymity. Biden’s current top aide, Ron Klain, is preparing to leave the job in the coming weeks. Since his role as the administration’s COVID-19 response coordinator, Zients has returned to the White House in a low-profile position to work on staffing matters for the remainder of Biden’s first term.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.

Topics

News Alert

Breaking News